Svetlana Mojsov was born in Skopje, the capital of Northern Macedonia, former Yugoslavia. She graduated from the University of Belgrade in 1971 with a degree in physical chemistry. In 1972 she was accepted in the graduate program at the Rockefeller University in New York and joined the laboratory of Professor Bruce Merrifield who developed the solid phase method for the synthesis of peptides and proteins. In her PhD thesis she reported the first solid phase synthesis of crystalline glucagon, graduating in 1978. She remained in the Merrifield laboratory first as a postdoctoral associate and later as a research associate and continued to work on improving the synthetic strategy for the solid phase peptide synthesis of glucagon. In 1983 she was appointed a member of the Endocrine Unit and Assistant in Biochemistry at the Massachusetts General Hospital and an Instructor in Medicine at Harvard Medical School, and the inaugural director of Howard Hughes peptide core facility at the Massachusetts General Hospital. Starting in 1983 she developed an independent research program to produce and study peptide products of the glucagon gene and showed that GLP-1(7-37) is secreted in the intestines. Mojsov’s collaborative studies with Joel Habener, Gordon Weir and David Nathan established that GLP-1(7-37) is a potent insulin secretagogue, an incretin, with therapeutic potential for treatment of Type 2 diabetes. In 1990 Mojsov returned to the Rockefeller University as an Assistant Professor and continued to work on GLP-1 biology and also collaborated with Professor Ralph Steinman. In 2002 she was promoted to a Research Associate Professor at the Rockefeller University. She is a co-inventor on a series of patents for the use of GLP-1(7-37) for treatment of Type 2 diabetes that were licensed by the Massachusetts General Hospital to Novo Nordisk Pharmaceutical Company who developed liraglutide, Victoza, and semaglutide, Ozempic, for treatment of Type 2 diabetes, and Saxenda and Wegovy for treatment of obesity. Mojsov is a recipient of numerous awards, including the 2023 Vin Future Prize, 2024 Pearl Meister Greengard Award, 2024 Tang Foundation Prize, 2024 Princess of Asturias Prize and 2024 Lasker-DeBakey Clinical Medical Research Award.